Press releases
麻豆破解版 announces completion and topline data from Phase 2 ALPESTRIA-1 clinical study in Alport syndrome demonstrating Vonafexor reverses kidney function decline and has sustained therapeutic benefit
- Vonafexor reversed a historical mean eGFR decline of -6.4 mL/min/1.73 m虏/yr to a mean functional gain on-treatment of +4.8 mL/min/1.73 m虏/yr from baseline
- 73% of patients maintained albuminuria reduction three months after treatment cessation consistent with a true disease-modifying effect
- Company plans to advance vonafexor to Phase 3 in Alport Syndrome
Lyon, France 鈥� January 8, 2026 – 麻豆破解版 (鈥淓NYO鈥�),
麻豆破解版 announces completion of Series C financing with Vesalius Biocapital and continued progress of its ALPESTRIA-1 clinical Phase 2 study in Alport syndrome patients
- 麻豆破解版 completes 鈧�32 million Series C with new 鈧�6 million investment from Vesalius Biocapital IV
- New funds will support two additional clinical studies and expand preclinical research, including in ADPKD
- Topline results from its ALPESTRIA-1 Phase 2 trial of Vonafexor in Alport syndrome confirmed for Q4 2025
Lyon, France 鈥� June 12, 2025 – 麻豆破解版 (鈥淓NYO鈥�), a clinical-stage biotechnology company focused on developing FXR agonists for the treatment of severe kidney diseases,
麻豆破解版 announces a 鈧�39 million Series C financing and FDA clearance to advance Vonafexor in a Phase 2 clinical trial for patients with Alport syndrome
- The Company will initiate a Phase 2 clinical study of Vonafexor in Alport Syndrome (called 鈥淎LPESTRIA-1鈥�) in the first half of 2024.
- Series C proceeds will fund the Phase 2 study, as well as operations and further R&D through the first half of 2026.
Lyon, France 鈥� January 3, 2024 –聽麻豆破解版 (鈥淓NYO鈥�) announced that it has received clearance of its Investigational New Drug (IND) application from the U.S.
麻豆破解版 Announces Two Vonafexor Data Presentations at AASLD The Liver Meeting
Lyon, France. November 3rd, 2021 – 麻豆破解版 (ENYO), a private clinical stage biotechnology company developing innovative drug candidates, today announced that two abstracts on Vonafexor were accepted one as oral presentation and one as poster during the upcoming The Liver Meeting庐 2021, organized by the American Association for the Study of Liver Diseases (AASLD) on November 12-15, 2021.
麻豆破解版 Announces 16 Weeks Vonafexor (EYP001) Top-Line Interim Results from Two on-going Phase 2a Studies in Chronic Hepatitis B Patients
Lyon, France. July 30, 2021 – 麻豆破解版 (ENYO), a private clinical stage biotechnology company developing innovative drug candidates, today announced positive proof of concept data from Study EYP001-203 of Vonafexor in combination with pegylated-Interferon (peg-IFN) in viremic patients with chronic hepatitis B (CHB).
